Noticias de KOD
Noticias del mercado
Últimas noticias sobre KOD — 235 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.
Kodiak Sciences Inc soars as pivotal clinical trial success fuels optimism, and stocks have been trading up by 87.2 percent. Key Takeaways UBS reiterates a Buy on Kodiak Sciences, tying an $80 price target to upcoming Phase 3 wet AMD data for tarcocimab and KSI-501 versus Eylea, well above the
Kodiak Sciences Inc surged as stocks have been trading up by 69.18 percent following highly positive clinical trial news Key Takeaways UBS reiterates a Buy on Kodiak Sciences with an $80 price target versus the current roughly $31 KOD share price, pointing to major upside if key trials deliver.
Kodiak Sciences Inc. (Nasdaq: KOD), una empresa de biotecnología precomercial centrada en la retina comprometida con la investigación, el desarrollo y la comercialización de terapias transformadoras, anunció hoy que la compañía informará los resultados principales de DAYBREAK, un estudio de fase 3 que evalúa tanto Zenkuda TM (tarcocimab tedromer) como KSI-501 (tabirafusp alfa tedromer) para el tratamiento de pacientes con degeneración macular húmeda relacionada con la edad, el lunes. 28 de septiembre de 2026.
Kodiak's DAYBREAK study evaluates Zenkuda and KSI-501 for wet age-related macular degeneration; topline results are scheduled for webcast at 8:30 a.m. ET.
Página 11 de 12